Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

Experimental Novartis Radiopharma Drug Shows Promise in Early Study

Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in ⁠patients...

Vasectomy Reversal More Cost-Effective Than IVF

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Todays Updates

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Todays Updates

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Latest News

Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in ⁠patients...

Most couples younger than 40 years can achieve pregnancy within typical $30,000-$40,000 employer fertility benefits with reversal, new research indicates.

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

News All Time

FDA Approves New Treatment for Women's Simple UTIs.

Now available in the U.S. is an antibiotic that is widely used in other nations. s.

During the Accountable Care Meeting, CMS Officials were pressed on the topic of scanner fraud.

"We would appreciate it if you could give the matter more immediate attention," one ACO member said.

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

Recommended News For You

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

When it comes to obesity-related cancers, where you shop for food matters

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

Breast cancer: A new target to eliminate dormant cells before they wake

Common intracellular toxin could help fight leukemia

Recommended Articles For You

Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers 

Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives 

Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential 

Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.

2.

For Localized Prostate Cancer, HIFU Is Not Worse Than Prostatectomy.

3.

Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'

4.

In women with extremely dense breasts, elevated MRI enhancement can help identify cancer risk.

5.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

1.

Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production

2.

Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results

3.

The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment 

4.

Effective Management Strategies for Sickle Cell Crisis: Insights from Medical Experts

5.

The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure 

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion

3.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V

5.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot